Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217641 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 10
- Study locations
NCT05217641 is a Phase 1 study of HIV Infections that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 108 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT05217641, a Phase 1 study of HIV Infections, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an open-label, multicenter, randomized phase 1 study to evaluate the safety and immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV trimer mRNA. These trimers are based on the BG505 MD39 native-like trimer reported in Steichen et al. Immunity 2016. The primary hypothesis is that the BG505 MD39.3 soluble and membrane-bound trimer mRNA vaccines will be safe and well-tolerated among HIV-uninfected individuals and will elicit autologous neutralizing antibodies.
Conditions Studied
Interventions
- BIOLOGICAL BG505 MD39.3 mRNA
- BIOLOGICAL BG505 MD39.3 gp151 mRNA
- BIOLOGICAL BG505 MD39.3 gp151 CD4KO mRNA
Study Locations (10)
New York
- New York Blood Center CRS [31801] - New York
- Columbia P&S CRS [30329] - New York
- University of Rochester Vaccines to Prevent HIV Infection CRS [31467] - Rochester
Massachusetts
- Bidmc Vcrs [32077] - Boston
- Brigham and Women's Hospital Vaccine CRS [30007] - Boston
Pennsylvania
- Penn Prevention CRS [30310] - Philadelphia
- University of Pittsburgh CRS [1001] - Pittsburgh
Alabama
- Alabama CRS [31788] - Birmingham
California
- UCLA Vine Street Clinic CRS [31607] - Los Angeles
Washington
- Seattle Vaccine and Prevention CRS [30331] - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2027-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05217641
The ClinicalTrials.gov registry entry for NCT05217641 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which BG505 MD39.3 mRNA is the first listed.
NCT05217641 reports 10 study locations spanning 6 distinct geographic areas - top geographies include New York, Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05217641 about?
NCT05217641 is a clinical study titled "A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants". This is an open-label, multicenter, randomized phase 1 study to evaluate the safety and immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV trimer mRNA. These trimers are based on the BG505 MD39 native-like trimer reported in Steichen et al. Immunity 2016. The primar...
What is the current status of trial NCT05217641?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2022-02-11. Estimated completion is 2027-06-24.
What conditions does trial NCT05217641 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT05217641?
The interventions under investigation include: BG505 MD39.3 mRNA (BIOLOGICAL), BG505 MD39.3 gp151 mRNA (BIOLOGICAL), BG505 MD39.3 gp151 CD4KO mRNA (BIOLOGICAL).
Who is sponsoring clinical trial NCT05217641?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05217641 being conducted?
This trial has 10 study locations across Alabama, California, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.